[1] CHANG Y,JEONG S W,YOUNG JANG J,et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma[J].Int J Mol Sci,2020,21(21):8165. [2] LI S,NIU M,DENG W,et al. Efficacy of chemotherapy versus transcatheter arterial chemoembolization in patients with advanced primary hepatic neuroendocrine carcinoma and an analysis of the prognostic factors:a retrospective study[J].Cancer Manag Res, 2021,13(10):9085-9093. [3] 张炎锋,苗炜宇,景静源. 肝动脉灌注化疗栓塞对原发性肝癌介入治疗效果及对患者血清指标和生活质量的影响[J].医药论坛杂志,2022,43(9):80-83. [4] 胡泽玉,杨清瑞,周铖,等. 肝癌化疗耐药机制及中药干预研究进展[J].中国实验方剂学杂志,2022,28(14):254-261. [5] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志,2011,16(10):929-946. [6] 王军. 养正消积胶囊辅助治疗对原发性肝癌患者肿瘤标志物及生活质量的影响[J].中国老年学杂志,2015,35(20):5827-5829. [7] LEONE P,SOLIMANDO A G,FASANO R,et al. The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment[J].Vaccines (Basel),2021,9(5):532. [8] 肖祖林,任真,叶思思,等. 养正消积胶囊联合化疗治疗非小细胞肺癌的疗效及安全性的Meta分析[J].中药新药与临床药理,2020,31(6):735-740. [9] 周津卉,谢锋. 改良格拉斯哥评分和血清癌胚抗原水平对结直肠癌肝转移的预测价值[J].实用肿瘤杂志,2022,37(5):424-432. [10] XU K,WU C L,WANG Z X,et al. VEGF family gene expression as prognostic biomarkers for alzheimer's disease and primary liver cancer[J].Comput Math Methods Med,2021,15(20):3422393. [11] 魏若愚,黎春红,叶进军. 胃癌ESD术后CA724、NLR、MLR、PLR水平与术后复发的关系[J].海南医学,2022,33(18):2337-2339. [12] 杨结,谢万珍,刘树业. 血清肿瘤标志物联合检测在原发性肝癌诊断中的价值研究[J].中国中西医结合外科杂志,2022,28(3):352-358. [13] ALHARBI K S,ALMALKI W H,ALBRATTY M,et al. The therapeutic role of nutraceuticals targeting the Nrf2/HO-1 signaling pathway in liver cancer[J].J Food Biochem,2022,46(10):14357.
2023, Vol. 40 
